← Back to Search

Radiation Therapy

Genu-Sparing Whole Brain Radiation for Brain Cancer

N/A
Recruiting
Led By Kristin Janson
Research Sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Histologic proof or unequivocal cytologic proof solid tumor malignancy from either the primary or any metastatic site
Karnofsky Performance Status (KPS) score ≥70
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 4, 6 and 12 months
Awards & highlights

Study Summary

This trial is testing whether a certain type of brain radiation can help preserve brain function in patients with brain cancer.

Who is the study for?
This trial is for adults over 18 with brain metastases who can consent to treatment, have a performance status score of ≥70, and are expected to live at least 6 more months. They must be able to use contraception and have not had whole brain radiation before. Non-English speakers, those with serious illnesses preventing protocol adherence or MRI contraindications, are excluded.Check my eligibility
What is being tested?
The study tests genu-sparing whole brain radiation therapy (WBRT) aimed at preserving cognitive and neuropsychiatric functions in patients with brain metastases. It's designed for those who've possibly undergone prior stereotactic radiosurgery but haven't received WBRT.See study design
What are the potential side effects?
While the trial focuses on sparing the genu to preserve function, side effects may include typical radiation-related issues such as fatigue, hair loss, skin irritation at the treated area, headaches, nausea and potential cognitive changes.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My cancer diagnosis is confirmed by lab tests on tissue or fluid samples.
Select...
I am able to care for myself but may not be able to do active work.
Select...
I can understand and am willing to sign the consent form.
Select...
I have had radiosurgery for brain cancer spread.
Select...
I am scheduled for whole brain radiation therapy for brain metastases.
Select...
I am 18 years old or older.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~4, 6 and 12 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 4, 6 and 12 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Rate of change of cognitive function
Secondary outcome measures
Rate of change in QoL
Rate of change in other frontally-mediated functions
Rate of change of cognition
+2 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: Corpus Callosum Genu-Sparing Whole Brain Radiation TherapyExperimental Treatment1 Intervention
Genu-sparing whole brain radiation therapy (GS-WBRT) 30 Gy in 3 Gy per fraction
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
whole brain radiation therapy
2016
Completed Phase 1
~20

Find a Location

Who is running the clinical trial?

Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsLead Sponsor
556 Previous Clinical Trials
32,856 Total Patients Enrolled
Kristin JansonPrincipal InvestigatorThe SKCCC at Johns Hopkins

Media Library

Genu-Sparing Whole Brain Radiation Therapy (Radiation Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT03223922 — N/A
Brain Tumor Research Study Groups: Corpus Callosum Genu-Sparing Whole Brain Radiation Therapy
Brain Tumor Clinical Trial 2023: Genu-Sparing Whole Brain Radiation Therapy Highlights & Side Effects. Trial Name: NCT03223922 — N/A
Genu-Sparing Whole Brain Radiation Therapy (Radiation Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03223922 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What eligibility criteria must be met to partake in this research?

"To participate in this medical trial, individuals should possess a diagnosis of brain cancer and be aged between 18-100 years old. A total of 24 participants are being sought after."

Answered by AI

How many individuals are being recruited to participate in this research?

"Affirmative. Data hosted on clinicaltrials.gov indicates that this medical experiment, which was initially published on July 19th 2017, is actively recruiting patients. Approximately 24 volunteers have to be sourced from 3 separate trial sites."

Answered by AI

Does this experiment admit octogenarians?

"As per the stated inclusion criteria, this trial is open to adults between 18 and 100 years of age."

Answered by AI

Is this research venture still actively recruiting participants?

"Affirmative, the information found on clinicaltrials.gov displays that this trial is still recruiting participants. Initiated on July 19th 2017, this medical study seeks to enrol 24 people from 3 different sites."

Answered by AI
~5 spots leftby Dec 2025